Objective To explore the impact of antimicrobial volume-based procurement (VBP) and classification management policy on the clinical use of carbapenem antibiotics. Methods Changing trend in defined daily doses (DDDs), procurement cost (Cost), defined daily dose cost (DDDc), and DDDs per 1 000 inhabitants daily (DID) of carbapenem antibiotics in all levels of medical institutions were analyzed by Mann-Kendall trend test. May 1, 2020 was taken as the intervention cut-off point of VBP policy, September 2021 was as intervention cut-off point of cla-ssification management list. The impact of VBP and classification management policy on the clinical use of carbape-nem antibiotics were studied by interrupted time series analysis. Results After implementing VBP policy, the DDDs and DID of carbapenem antibiotics increased obviously, but the long-term trend didn’t change significantly. Compared with before the implementation of the policy, the cost and DDDc of carbapenem antibiotics decreased immediately, the long-term trend of DDDc changed significantly, but the long-term trend of cost didn’t change significantly. The DDDs and Cost of carbapenem antibiotics decreased immediately after the update of classification ma-nagement list, but the long-term downward trend was not significant, and DDDc presented a long-term upward trend. Conclusion VBP policy reduces the DDDc and short-term cost of carbapenem antibiotics, but its long-term impact on DDDs, cost and DID is limited. Classification management has limited impact on the use of carbapenem antibiotics in medical institutions.